Page 2 - Solid Bioscience News Today

Pfizer now has the regulatory O.K. to resume pivotal tests of its gene therapy for Duchenne muscular dystrophy—but with new limitations and safety measures. The FDA had placed a clinical hold on the study late last year following a patient death.

Equities research analysts expect that Solid Biosciences Inc. (NASDAQ:SLDB – Get Rating) will post earnings per share of ($0.18) for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Solid Biosciences’ earnings, with estimates ranging from ($0.20) to ($0.17). Solid Biosciences posted earnings of ($0.19) per share during the same quarter […]

Engaged Capital initiated a 9.96% position in the health-care, administrative-services tech firm, equal to 8,553,155 Evolent Health shares. That position has remained unchanged, as noted by Engaged Capital’s latest disclosure. What has changed is that Engaged and Evolent entered into a cooperation agreement as of Dec. 21. Per the agreement, Evolent will increase the size of its board by one to accommodate the appointment of an Engaged representative to serve until at least next year’s annua...